血管功能障碍与疾病二级预防多学科博士研究员
BHF Multidisciplinary Doctoral Training Programme (Fixed Term)
原帖优先:申请材料、截止时间与资格以原帖和学校官方说明为准。
AI 中文速览
- 研究内容
- 本项目聚焦于血管功能障碍与疾病的二级预防,旨在开发创新、跨学科的方法来阻止、稳定和逆转高危患者的血管疾病。学生将在四个相互关联的研究主题中开展工作:定义疾病(深度表型分析、成像和患者分层)、阐明机制与生物标志物(多组学和基因发现)、调控细胞死亡与炎症(系统免疫学与治疗靶向)、以及维持血管稳定性(细胞生物学、生物力学与再生方法)。
- 申请条件
- 申请者应持有或预计获得生物化学、生物医学、生物工程或相关生命科学学科的一等或二等上学士学位(或同等学历)。
- 待遇
- 提供为期4年的全额资助奖学金,包括:按标准BHF费率发放的免税生活津贴(目前为每年21,747英镑,随4年上涨);Home标准的大学学费;耗材预算;会议差旅补贴;用于访问项目内合作伙伴的额外资金。
- 申请方式
- 原文未说明具体提交地址,申请截止日期为2026年12月23日(23:59:59)。学生必须于2027年10月入学。
- 材料清单
- 简历 (CV)
- 学术成绩单 (Academic transcripts)
- 求职信/个人陈述 (Covering letter/personal statement)
由 gemini-2.5-flash-lite 生成,博士岗判定置信度 100%。
岗位信息
- 截止
- (Europe/London) 剩 55 天
- 学科
- 生命科学
- 合同类型
- 奖学金
- 原文薪资
- GBP 21,747 / 年(税前)
- 估算假设
- 单身、无子女、雇佣合同的粗略估算,以学校 offer 为准;扣除率 18%;汇率日期 2026-10-01
- 原帖发布
- 本站收录
- 内容更新
- 来源
- University of Cambridge 博士奖学金与 Studentships · 最近核对 2026-10-14
- 详情核验
判定依据(原文摘录)
- 这是一项4年制博士培养机会
This structured 4-year doctoral training programme is designed to provide a level of integration and breadth beyond that of a traditional PhD.
- 要求相关学科的学士学位(一等或二等上)
Applicants should hold, or expect to obtain, a first or upper second-class undergraduate degree (or equivalent) in a relevant discipline such as Biochemistry, Biomedical sciences, Bioengineering or related life science subject.
原文
Secondary Prevention of Vascular Dysfunction and Disease
University of Cambridge, in collaboration with the University of Oxford
Start date: October 2027
Fully funded studentships
Applications are invited for the second intake of the new British Heart Foundation (BHF) 4-Year Multidisciplinary Doctoral Training Programme that brings together researchers from the Universities of Oxford and Cambridge, with a focus on Secondary Prevention of Vascular Dysfunction and Disease. This flagship programme will train the next generation of cardiovascular scientists to develop innovative, cross-disciplinary approaches to halt, stabilise and reverse vascular disease in high-risk patients.
Students will be admitted to either the University of Oxford (up to 8 studentships) or the University of Cambridge (2 studentships) and will benefit from co-supervision, training, collaboration and access to world-class research infrastructure across partner institutions.
Instructions for applying to Cambridge are given below.
Vascular diseases, including coronary artery disease, stroke and aortic aneurysm, remain leading causes of death and disability worldwide. While acute care has advanced significantly, therapeutic innovation aimed at preventing disease progression and reversing established pathology has stagnated. We will identify new targets for secondary prevention and disease regression, ultimately reducing cardiovascular risk in vulnerable populations. Recent transformative technological advances, including multi-omics and AI-enhanced imaging, provide unprecedented new opportunities to gain novel mechanistic insights and develop urgently needed treatments.
In a truly multidisciplinary programme, students will work across four interconnected research themes:
Defining disease - Deep phenotyping, imaging and patient stratification Elaborating mechanisms and biomarkers - Multi-omics and genetic discovery Modulating cell death and inflammation - Systems immunology and therapeutic targeting Maintaining vascular stability - Cell biology, biomechanics and regenerative approaches
The programme leverages world-leading infrastructure including BHF Centres of Research Excellence at both institutions, large-scale clinical datasets (e.g. UK Biobank), advanced imaging platforms, spatial transcriptomics hubs, and cutting-edge immunophenotyping facilities.
This structured 4-year doctoral training programme is designed to provide a level of integration and breadth beyond that of a traditional PhD. To establish a firm foundation for doctoral research, in year 1, students will undertake core research and bespoke specialist training, as well as two 12-week laboratory rotations in complementary disciplines, before progressing to a three-year main research project. Cross-institutional symposia and cohort-building activities will feature in all four years, and there will be opportunities to interact with pharmaceutical and biotechnology partners, and to undertake training in entrepreneurship, innovation and commercial translation. The programme aims to produce graduates equipped for careers in academia, industry, biotechnology, healthcare, policy and beyond.
Each fully funded 4-year studentship includes:
-A tax-free stipend at the standard BHF rate (currently £21,747/year; rising over the 4 years)
-University tuition fees at the home rate
-Consumables budget
-Travel allowance for conferences
-Additional funds to visit partners within the programme
Studentships will fully fund those who meet the UK residency requirements (home fees). International students who are able to meet the additional costs of overseas tuition fees through other scholarships or funding schemes will also be considered.
Students must commence in October 2027.
Eligibility Applicants should hold, or expect to obtain, a first or upper second-class undergraduate degree (or equivalent) in a relevant discipline such as Biochemistry, Biomedical sciences, Bioengineering or related life science subject. We particularly encourage applications from candidates with interdisciplinary interests and from groups underrepresented in cardiovascular research.
Equality, Diversity and Inclusion We are committed to fostering an inclusive research culture aligned with the BHF "Igniting Change" strategy. Recruitment will be conducted transparently and equitably. We actively encourage applications from candidates of all backgrounds.
Application Process
Applicants should submit:
-CV
-Academic transcripts
-Covering letter/personal statement (